Abstract

BackgroundMycoplasma hominis is a human urogenital pathogen involved in gynaecological, neonatal and extra-genital infections. However, no versatile genetic tools are currently available to study the pathogenicity of this bacterium. Targeting-Induced Local Lesions IN Genomes (TILLING) is a reverse-genetic method that combines point mutations induced by chemical mutagenesis with a DNA screening technique. We used ethyl methanesulfonate (EMS) that introduces C-G to T-A transition mutations to generate a library of M. hominis mutants. As a proof of concept, mutagenized organisms were screened for mutations in two target genes previously associated with the mycoplasma pathogenicity, the vaa gene encoding an adhesin lipoprotein and the oppA gene encoding the main ectoATPase of the bacterium. The resulting mutants were evaluated using functional assays, an adhesion to HeLa cell assay for vaa-mutants and an ATPase activity test for oppA-mutants.ResultsA 1200-clone library was generated by exposing M. hominis PG21 to 9 mg/mL EMS for 3 h. To identify mutants of interest, targeted gene fragments were amplified, heat-denatured, slowly reannealed and digested with the mismatch-specific endonuclease ENDO1. If multiple alleles were present in the PCR amplicons, these alleles formed heteroduplexes during reannealing that were specifically cleaved by ENDO1 at mismatching positions.A total of four vaa-mutants and two oppA-mutants harbouring missense mutations were obtained and fully sequenced. Zero to eight additional mutations were identified in the genomes of each mutant. The vaa-mutants were tested for adhesion to immobilized HeLa cells but their adhesion was not significantly different from the adhesion of M. hominis PG21. One of the two oppA-mutants that were tested for ATPase activity presented a higher affinity for its ATP substrate than the parental strain.ConclusionFor the first time, we demonstrated that M. hominis gene-targeted mutants could be successfully obtained using this TILLING strategy. In the absence of robust genetic tools for studying M. hominis, the TILLING strategy that can target any gene of the genome could help to elucidate gene functions and to better understand the pathogenesis of this human pathogenic species.

Highlights

  • Mycoplasma hominis is a human urogenital pathogen involved in gynaecological, neonatal and extragenital infections

  • For the generation of the mutant library, a concentration of 9 mg/ml ethyl methanesulfonate (EMS) applied for 3 h that resulted in 75% killing was chosen according to the bibliography [11]

  • Screening of the M. hominis mutant library for vaa- and oppA-mutants To screen the library for vaa-mutants, a 1692-bp PCR fragment of the M. hominis genome encompassing the 1295 nucleotides at the 5′-end of the vaa gene (MHO_3470, 1416 bp [2]) was targeted (Table 1, Fig. 2)

Read more

Summary

Introduction

Mycoplasma hominis is a human urogenital pathogen involved in gynaecological, neonatal and extragenital infections. No versatile genetic tools are currently available to study the pathogenicity of this bacterium. As a proof of concept, mutagenized organisms were screened for mutations in two target genes previously associated with the mycoplasma pathogenicity, the vaa gene encoding an adhesin lipoprotein and the oppA gene encoding the main ectoATPase of the bacterium. Mycoplasma hominis is a human urogenital pathogen involved in gynaecological, neonatal and extra-genital infections [1]. A conjugal transfer of the transposon Tn916 from Streptococcus faecalis to M. hominis was reported 30 years ago [3], no versatile genetic tools are currently available for this species. The lack of genetic engineering tools for M. hominis has limited our capacity to modify its genome in order to elucidate gene functions and to understand its pathogenesis

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call